The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

PURPOSEGEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment ...

The PEARL study confirms fremanezumab's long-term effectiveness and safety in migraine prevention over two years. Quiver AI Summary Teva Pharmaceutical Industries Ltd. announced the final analysis ...

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS ...

NEWS 25 June 2025 Does using ChatGPT change your brain activity? Study sparks debate Scientists warn against reading too much into a small experiment generating a lot of buzz.

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

By Connor Hart Shares of Exelixis climbed after the company reported what it called positive topline results from a trail studying a potential treatment for colorectal cancer.

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseSTAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR ...